Scientists test novel way to detect pancreatic cancer from biopsy fluid
NCT ID NCT03791073
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new technique called EXPEL to find biomarkers for pancreatic cancer. Researchers will analyze the fluid used to preserve biopsy samples from 200 patients with suspected pancreatic cancer. The goal is to identify proteins and other molecules that could help diagnose the disease earlier and more accurately.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better and earlier diagnosis of pancreatic cancer, and help doctors understand the disease more deeply.
- What could go wrong
- This is an early-stage observational study, not a treatment trial. The new method may not prove reliable enough for routine use, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONCOLOGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Uhmontpellier
RECRUITINGMontpellier, Montpellier, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Blood and gut clues may flag pancreatic cancer risk early
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- Could a breathing exercise and music tame cancer treatment fatigue?
- A sound wave that could expose hidden pancreatic cancer?